Ozempic and other GLP-1 receptor agonists affect fertility in two opposing ways. In women with PCOS or obesity, GLP-1 drugs frequently restore ovulation and improve fertility. Simultaneously, GLP-1 drugs may reduce the effectiveness of oral contraceptives by delaying gastric emptying, causing unintended pregnancies in women who assumed they were protected. The FDA issued a label update addressing this interaction in 2023.
The fertility effects of GLP-1 drugs are only beginning to be systematically studied, but the real-world data is already forcing clinical practice to change. OB-GYNs are seeing patients conceive on Ozempic while on oral contraceptives they had relied on for years. Reproductive endocrinologists are using semaglutide as a first-line intervention for PCOS patients who failed to ovulate on clomiphene or letrozole alone. The drug that millions of women use for weight management has a profound and underappreciated relationship with the reproductive system.
GLP-1 Drugs Can Restore Ovulation in PCOS: The Fertility Benefit
Polycystic ovary syndrome (PCOS) is the most common cause of anovulatory infertility, affecting approximately 10 percent of reproductive-age women worldwide. The hormonal core of PCOS involves insulin resistance, elevated androgens, and disrupted LH pulsatility, all of which prevent normal follicular development and ovulation. GLP-1 receptor agonists address the insulin resistance component directly, and the downstream effects on ovulation are measurable.
A 2023 study published in The Journal of Clinical Endocrinology and Metabolism found that semaglutide treatment in obese women with PCOS restored regular menstrual cycles in 63 percent of participants within six months, compared to 12 percent in the diet-only control group. The mechanism operates through multiple pathways: improved insulin sensitivity reduces hyperinsulinemia, which in turn reduces ovarian androgen production. Lower androgens allow FSH to recruit follicles more effectively and permit normal ovulation to occur.
The fertility implications extend beyond PCOS. Women with obesity-related anovulation, hypothalamic amenorrhea associated with metabolic dysfunction, and irregular cycles driven by insulin resistance all represent populations where GLP-1 therapy may restore fertility. Reproductive endocrinologists are increasingly prescribing semaglutide as preconception preparation in obese patients planning IVF, given evidence that weight loss before retrieval significantly improves egg quality and implantation rates.
The timeline for fertility restoration matters clinically. Ovulation can resume within six to twelve weeks of starting a GLP-1 drug, before meaningful weight loss has occurred. This reflects a direct metabolic effect, not merely a weight-mediated effect. A woman who has been anovulatory for years may become ovulatory while still in the obese BMI range, simply because her insulin sensitivity has improved. This is why contraception counseling must accompany every GLP-1 prescription for women of reproductive age who do not wish to conceive.
The Oral Contraceptive Interaction: Why Pregnancies Are Happening on Ozempic
Oral contraceptives depend on consistent gastric emptying for reliable absorption. A pill taken at 8 AM normally reaches the small intestine and achieves peak plasma concentration within one to two hours. GLP-1 receptor agonists profoundly slow gastric emptying, a mechanism that contributes to their satiety effects but also delays the absorption of anything taken orally, including oral contraceptives.
The FDA updated semaglutide labeling in 2023 to include a recommendation to switch to a non-oral contraceptive or add a barrier method for four weeks after starting the drug and for four weeks after each dose escalation. The clinical implication is significant: the women most likely to be prescribed Ozempic are also the population for whom oral contraceptives are most commonly prescribed. The prescriber of the GLP-1 and the prescriber of the contraceptive are often different physicians who may not communicate about the interaction.
The unintended pregnancy pattern that has emerged clinically involves women who have been stable on oral contraceptives for years and who start a GLP-1 drug without being counseled about the absorption interaction. The contraceptive appears to be working because no one has missed a dose. What is actually happening is that plasma contraceptive hormone levels are consistently lower than expected due to delayed and inconsistent absorption, reducing the margin of suppression against ovulation.
Non-oral contraceptive methods are not affected by this mechanism. Intrauterine devices (hormonal and copper), subdermal implants, the contraceptive patch, vaginal rings, and injectable contraceptives all deliver hormones through routes that bypass oral absorption entirely. Any woman starting a GLP-1 receptor agonist who relies on an oral contraceptive for pregnancy prevention should discuss transitioning to one of these alternatives before starting the medication.
What Happens to a Baby If You Conceive While on Semaglutide
Semaglutide is currently contraindicated in pregnancy under FDA labeling, based on animal reproductive toxicity data. Rat and rabbit studies at doses proportional to human exposure showed fetal growth restriction, skeletal abnormalities, and increased fetal mortality. Human data is limited because clinical trials excluded pregnant women, but the mechanistic concern is serious enough to recommend discontinuation before conception.
GLP-1 receptors are expressed in fetal tissue, including the developing pancreas. Continuous exposure to an exogenous GLP-1 agonist during organogenesis raises theoretical concerns about pancreatic beta-cell development. Animal data cannot be directly extrapolated to humans, but no GLP-1 manufacturer has conducted the embryotoxicity studies that would establish human safety in the first trimester.
Real-world pregnancy outcomes on semaglutide are being tracked through the Novo Nordisk pregnancy registry (NCT04747418) and through pharmacovigilance reporting. Interim reports as of 2025 show no clear signal of a specific malformation pattern in the limited number of documented first-trimester exposures, but the numbers are too small for definitive safety conclusions. The Endocrine Society’s position is that the theoretical risks are sufficient to recommend discontinuation two months before attempting conception, based on semaglutide’s half-life of approximately one week.
Women who discover a pregnancy while on a GLP-1 drug should stop the medication immediately and contact their OB-GYN. Attributing a loss or complication to the GLP-1 exposure requires careful consideration of baseline risk and timing of exposure relative to the gestational window.
How to Use Contraception Safely While on GLP-1 Drugs
The safest contraception choices while on a GLP-1 receptor agonist are methods that completely bypass oral absorption. A hormonal IUD (Mirena, Kyleena, Liletta) provides highly effective contraception for three to eight years and is unaffected by gastric emptying. The copper IUD provides non-hormonal contraception with no drug interaction risk. A subdermal implant (Nexplanon) delivers etonogestrel continuously at a stable rate through the skin.
If an oral contraceptive is the only option or the strongly preferred option, the FDA’s interim guidance recommends adding a barrier method during dose initiation and dose escalation phases. Whether long-term oral contraceptive use at stable GLP-1 doses maintains adequate contraceptive efficacy remains an open question with insufficient data.
Women with PCOS who start a GLP-1 drug specifically to restore fertility face a paradoxical situation: the drug may restore ovulation before they want to conceive. These women need a clear ovulation monitoring plan and contraception coverage during the early phase of treatment if they are not yet ready for pregnancy. Using ovulation predictor kits monthly during the first six months of GLP-1 therapy helps identify when ovulatory cycles return, which is clinically relevant both for contraception decisions and for fertility planning.
When to Stop Ozempic Before Trying to Conceive
The standard recommendation is to discontinue semaglutide at least two months before attempting conception. Semaglutide has a half-life of approximately seven days, which means roughly 95 percent of the drug is cleared from the body within five weeks. The two-month window adds a safety buffer above the pharmacokinetic minimum and allows the body’s natural GLP-1 signaling to re-establish baseline function before conception.
The practical consequence of this recommendation is important for women who have achieved significant weight loss on a GLP-1 drug. Stopping semaglutide two to three months before a planned conception attempt may result in partial weight regain during that window. The fertility benefits of the weight loss, including restored ovulation and improved egg quality, persist beyond drug discontinuation. Metabolic improvements in insulin sensitivity also persist for several months after stopping, though they gradually attenuate.
For women with PCOS who restored ovulatory cycles on semaglutide, the crucial question is whether ovulation continues after drug discontinuation. In women who achieved significant weight loss, many maintain regular cycles post-discontinuation. In women who had minimal weight loss but ovulation restoration driven by direct metabolic effects, cycles may become irregular again within one to three months of stopping. A reproductive endocrinologist can help design a preconception strategy that times drug discontinuation appropriately relative to fertility treatment.
Liraglutide (Victoza, Saxenda) and tirzepatide (Mounjaro, Zepbound) have similar pregnancy contraindication profiles and similar washout recommendations. Any GLP-1 receptor agonist or GIP/GLP-1 co-agonist should be approached with the same two-month preconception washout window as semaglutide until more specific data exists for each agent.
Frequently Asked Questions
Can Ozempic cause unintended pregnancy?
Yes. Ozempic slows gastric emptying, which reduces the absorption and blood levels of oral contraceptives. This can lower contraceptive effectiveness enough to allow ovulation and unintended pregnancy. The FDA updated Ozempic labeling in 2023 recommending backup contraception when starting or escalating the dose. Women who use oral contraceptives should switch to a non-oral method or use a barrier method as backup.
Does Ozempic help with PCOS fertility?
GLP-1 drugs including semaglutide improve ovulation rates in women with PCOS by reducing insulin resistance and lowering hyperandrogenism. A 2023 study in JCEM found 63 percent of obese PCOS patients restored regular menstrual cycles within six months on semaglutide, compared to 12 percent in the diet-only group. Ovulation can resume before significant weight loss occurs, reflecting a direct metabolic effect.
Is Ozempic safe during pregnancy?
Ozempic is contraindicated during pregnancy. Animal reproductive studies showed fetal growth restriction and skeletal abnormalities at doses comparable to human exposure. GLP-1 receptors are expressed in fetal tissue. The Endocrine Society recommends stopping semaglutide at least two months before attempting conception. Women who become pregnant while on Ozempic should stop immediately and consult their OB-GYN.
How long after stopping Ozempic can I get pregnant?
The standard recommendation is to wait at least two months after stopping semaglutide before attempting conception. Semaglutide has a seven-day half-life and is pharmacokinetically cleared within five weeks. The two-month window provides a safety buffer above this minimum. Most reproductive endocrinologists recommend stopping GLP-1 drugs two to three months before a planned conception attempt.
What contraception should I use while on Ozempic?
Non-oral contraceptive methods are the safest choice while on Ozempic. Hormonal IUDs, copper IUDs, subdermal implants, the contraceptive patch, vaginal rings, and injectable contraceptives are all unaffected by slowed gastric emptying. If you prefer to stay on oral contraceptives, use a backup barrier method during the first four weeks of Ozempic use and for four weeks after each dose escalation.
Does tirzepatide have the same fertility effects as Ozempic?
Tirzepatide is a dual GIP/GLP-1 receptor agonist with similar gastric emptying effects and a similar pregnancy contraindication to semaglutide. Apply the same oral contraceptive interaction precautions and the same two-month preconception washout recommendation. Specific fertility studies for tirzepatide in PCOS are underway, but the mechanistic effects on insulin resistance and ovulation are expected to be comparable or superior to semaglutide alone.
